** Shares of telehealth firm Hims & Hers HIMS.N fall 19.22% to $41.45 premarket

** Co says may no longer be able to sell compounded versions of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy, after US FDA removes it from shortage list

** Adds the move could lead to customers cancelling their subscriptions, affecting revenue

** Shares have risen 5 fold in the last 12 months

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))